The authors concluded that SIRT1 is involved in the acquisition of the aggressive behavior associated with endometrial carcinoma, and it can be a promising therapeutic target candidate, underlying that the EX527, as a SIRT1 inhibitor, may be a useful agent for the treatment of endometrial carcinoma [51]. Here, SIRT1 is linked to endometrial carcinoma.